| 22037 |
Buprenorphine/Naloxone |
Zubsolv® |
As substitution treatment for opioid drug dependence, within a framework of medical, social and psychological treatment. The intention of the naloxone component is to deter intravenous misuse. Treatment is intended for use in adults and adolescents over 15 years of age who agreed to be treated for addiction. |
Rapid Review complete |
21st June 2022 |
 |
| 22056 |
Buprenorphine |
Buvidal® |
Treatment of opioid dependence within a framework of medical, social and psychological treatment. Treatment is intended for use in adults and adolescents aged 16 years or over. |
Rapid Review complete |
5th June 2024 |
|
| - |
Buprenorphine/Naloxone |
Suboxone® |
Management of opiate addiction |
NCPE Assessment Process Complete |
22nd May 2014 |
|
| - |
Burosumab |
Crysvita® |
Treatment of X-linked hypophosphataemia (XLH) with radiographic evidence of bone disease in children 1 year of age and older and adolescents with growing skeletons. |
NCPE Assessment Process Complete |
12th March 2020 |
|
| 23005 |
Burosumab |
Crysvita® |
Burosumab (Crysvita®) is indicated for X-linked hypophosphataemia in adult patients. |
NCPE Assessment Process Complete |
1st August 2024 |
|
